Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04320615 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 452
- Enrollment target
NCT04320615 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 452 participants.
The verdict
NCT04320615, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 452 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.
Interventions
- DRUG Placebo
- DRUG Tocilizumab (TCZ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 452 participants |
| Start Date | 2020-04-03 |
| Est. Completion | 2020-07-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04320615
The ClinicalTrials.gov registry entry for NCT04320615 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 452 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04320615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04320615 about?
NCT04320615 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia". This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.
What is the current status of trial NCT04320615?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 452 participants. The study started on 2020-04-03. Estimated completion is 2020-07-28.
What interventions are being tested in trial NCT04320615?
The interventions under investigation include: Placebo (DRUG), Tocilizumab (TCZ) (DRUG).
Who is sponsoring clinical trial NCT04320615?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.